Product Name:5-bromo-2-methylpyrimidine

IUPAC Name:5-bromo-2-methylpyrimidine

CAS:7752-78-5
Molecular Formula:C5H5BrN2
Purity:97%
Catalog Number:CM104177
Molecular Weight:173.01

Packing Unit Available Stock Price($) Quantity
CM104177-100g in stock džœȤ
CM104177-250g in stock ƚŪdž

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:7752-78-5
Molecular Formula:C5H5BrN2
Melting Point:-
Smiles Code:CC1=NC=C(Br)C=N1
Density:
Catalog Number:CM104177
Molecular Weight:173.01
Boiling Point:
MDL No:MFCD07375143
Storage:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.